Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2023

Karaaslan S, Dilcher TL, Abdelsayed M, Goyal A. Significant outcomes associated with high-risk human papillomavirus negative Papanicolaou tests. J Am Soc Cytopathol. 2023;12(3):189-196.

Brown-Burke F, Hwang I, Sloan S, Hinterschied C, Helmig-Mason JB, Long M, et al. PRMT5 inhibition drives therapeutic vulnerability to combination treatment with BCL-2 inhibition in mantle cell lymphoma. Blood Adv. 2023;7(20):6211-6224.

Pakula H, Omar M, Carelli R, Pederzoli F, Fanelli GN, Pannellini T, et al. Distinct mesenchymal cell states mediate prostate cancer progression. bioRxiv. 2023.

Priest K, Le A, Gebregzabheir A, Nijmeh H, Reis GB, Mandell M, et al. Evolution of acquired resistance in a ROS1+ KRAS G12C+ NSCLC through the MAPK pathway. NPJ Precis Oncol. 2023;7(1):9.

Mavragani CP, Kirou KA, Seshan SV, Crow MK. Type I interferon and neutrophil transcripts in lupus nephritis renal biopsies: clinical and histopathological associations. Rheumatology (Oxford). 2023;62(7):2534-2538.

Nishida J, Cristea S, Bodapati S, Puleo J, Bai G, Patel A, et al. Peripheral blood TCR clonotype diversity as an age-associated marker of breast cancer progression. Proc Natl Acad Sci U S A. 2023;120(49):e2316763120.

Assaad MA, Shin N, Sigouros M, Manohar J, Antysheva Z, Kotlov N, et al. Deciphering the origin and therapeutic targets of cancer of unknown primary: a case report that illustrates the power of integrative whole-exome and transcriptome sequencing analysis. Front Oncol. 2023;13:1274163.

Kim JW, McKay RR, Radke MR, Zhao S, Taplin M-, Davis NB, et al. Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984. J Clin Oncol. 2023;41(4):871-880.

Xie Q, Schenck EJ, Yang HS, Chen Y, Peng Y, Wang F. Faithful AI in Medicine: A Systematic Review with Large Language Models and Beyond. medRxiv. 2023.

Sciascia S, Yazdany J, Moroni G, Becker JU, Seshan SV, Andrade D, et al. Clinical-Pathological Characteristics of Renal Injuries Identify Different Clusters in Patients With Antiphospholipid Antibodies. Kidney Int Rep. 2023;8(4):754-763.